Chrisandra Shufelt, MD, on using a cardiovascular risk score to guide hormone therapy candidacy at menopause.
News|Articles|July 31, 2026
Top FDA & regulatory news you missed in July, from Contemporary OB/GYN
Author(s)Joshua Fitch, Senior Editor
Fact checked by: Tracy Ann Politowicz
As we close out July, take a look back at key women's health FDA and other regulatory updates from the month.
Advertisement
Advertisement
July 2026 delivered a steady stream of clinically meaningful developments in women’s health, with readers gravitating toward stories highlighting regulatory updates, real-world data, and technology-driven innovation. The following articles represent key coverage from the month, presented in chronological order of publication and reflecting the topics shaping clinical conversations.
Related to this article
The October 30 update from the FDA follows the February 12, 2026 labeling changes to 6 menopausal hormone therapy products in which the agency also removed safety-related boxed warnings.
Neither maternal MOUD dose nor umbilical cord opioid levels were associated with neonatal opioid withdrawal syndrome severity.
Susan Reed, MD, on the need for menopause research funding, a clinical trials network, and studies in understudied groups and perimenopause.
Chrisandra Shufelt, MD, on why menopause is a window for cardiovascular prevention and the risk factors OB/GYNs should assess.
Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.
ACOG advises against GLP-1 receptor agonists in pregnancy and recommends considering discontinuation 1 to 2 months before conception.
Rhonda Voskuhl, MD, on a case series in which estriol and progesterone improved self-reported cognition in menopausal women at 12 months.
Advertisement
Advertisement